Revolutionizing Treatment of
Hypogonadism and Related


Acesis BioMed is a Colorado-based biomedical company focusing on treatment for hypogonadism (low testosterone).

  • Low T is also linked to indications such as NAFLD, obesity, and Klinefelter syndrome
  • Hypogonadism provides Acesis with a huge market of $3-4 billion. As an underserved indication, Acesis has an opportunity to provide treatment for anywhere between 10% and 40% of the global male population.
  • The company’s proprietary “first-in-class” peptide T modulator is expected to provide a safer solution to the existing Testosterone Replacement Therapy (TRT).

Key Facts


Acesi’s lead candidate ACE-167 is a non-hormonal treatment with a superior safety profile in preclinical studies.

Oral administration (once or twice daily) as opposed to existing injectable solutions eases access & facilitates compliance


Exceptional team with decades of experience in the pharmaceutical and Life Sciences.

Experienced leadership

Six-year development timeline to revenue


Declining T levels are a major global health care concern affecting between 10% and 40% of the male population

As the global male population ages, the market for Acesis' treatment only grows

Historical Funding

Dr Vassilios Papadopoulos has received more than $12 million research funding from multiple sources to support the groundwork leading to the understanding of the mechanism underlying steroidogenesis and identification of a novel target.

This led to the IP developed which forms Acesis’ core asset.

Acesis had a research agreement with Dr Papadopoulos’ lab at the Research institute of the McGill University Health Centre.